Subject ID:	Namecode:	
1a. Investigator taking responsibi	lity for the visit:	
1b. Coordinator taking responsibi	lity for the visit:	
2. Visit date:		
////		
If <u>Missed</u> , reason (select only o	·	
☐ Bad weather	☐ Subject on vacation	☐ Poor outcome
☐ Travel difficulty	☐ Visits too lengthy	☐ Good outcome
☐ Financial issue	☐ Investigator away	☐ Adverse event
☐ Poor health	☐ Clinic appointment not available	☐ Unknown
☐ Personal issue	☐ Site forgot to schedule	☐ Other
☐ Work issue	☐ Difficulty contacting subject	
OUT OF WINDOW		
☐ Visit was completed out of wind	dow	
1. Reason visit was completed ou	t of window (select only one):	
☐ Bad weather	☐ Subject on vacation	☐ Poor outcome
	☐ Visits too lengthy	☐ Good outcome
☐ Travel difficulty	☐ Investigator away	☐ Adverse event
☐ Travel difficulty ☐ Financial issue	ooagato. a.r.a,	
-	☐ Clinic appointment not available	☐ Unknown
☐ Financial issue	• •	☐ Onknown ☐ Other
☐ Financial issue ☐ Poor health	☐ Clinic appointment not available	

CITY Follow-up Visit Worksheet	
Subject	ID: Namecode:
TYPE O	F CONTACT- COMPLETE AT 2 WEEK VISIT
1.	Select the type of contact O In Clinic Visit OVideo Telehealth OPhone Call OOther 1a. If Other, describe:
CONFIR	M COMPLETION OF THE FOLLOWING:
BGM RE	
1.	What is the average number of fingerstick readings the participant reports having done each day over the last 7 days? [Range: 0-30]
	Was the participant's BGM(s) downloaded at the visit? O Yes, all BGM downloaded O Yes, only one BGM downloaded ONo 2a. If Yes, average number of fingerstick readings per day over the last 14 days: [Range: 0.0-30.0]
INSULIN	I USE
	Has insulin delivery method changed since last study visit? O Yes ONo 1a. If Yes, Date of Change: *If Yes please update insulin changes by entering an insulin form
	Current Method of insulin administration: O Pump O Injections If "Injections" answer question 3 and sub-questions below. If "Pump" answer question 4 and sub-questions below.

3.	Injection Users:	
	*Record any changes or new types of insulin on the Insulin Form	
3a. Long-acting or intermediate-acting insulin (such as Lantus, Levemir, U500, or NPH) :		
	i. Average number of injections per day over the past 7 days: injections per day [0 - 20] Unknown Do not use	
	ii. Average units of insulin per day on over the past 7 days: units per day [0.0 - 300.0] Unknown Do not use	
	3b. Short-acting or rapid-acting insulin (such as Humalog, Novolog, Apidra, Fiasp or Regular):	
	i. Average number of injections per day over the past 7 days: injections per day [0 - 20] Unknown Do not use	
	ii. Average units of insulin per day on average over the past 7 days: units per day [0.0 − 300.0] □ Unknown □ Do not use	
4.	Pump Users: *Obtain information from pump download over the past 14 days if possible*	
	4a. Average total daily insulin in units over the past 14 days: units per day [0.0-300.0] Unknown	
	4b. Average total daily basal insulin in units:	
	units per day [0.0-200.0]	
	4c. Average number of boluses per day:	
	boluses per day [0-50]	
	☐ Check here if information from pump download	
NON-ST	FUDY CGM INITIATION	
1. Did	the participant initiate using a non-study real-time CGM or flash glucose monitor since randomization?	
	O Yes, real time CGM O Yes, flash glucose monitor O No	
	1a. If Yes, number of days per week the participant currently uses a non-study real-time CGM or flash glucose monitor: [0-7]	
	1b. Start date of non-study real-time CGM or flash glucose monitor: / mm/dd/yy	

2.	Has the participant initiated using automated insulin delivery or a low glucose suspend feature since randomization?	
	O Yes O No	
	2a. Start date of automated insulin delivery or low glucose suspend feature?	
	/ / mm/dd/yy	

CITY Diabetes Medical History Updates (A) Worksheet	
Subject ID: Namecode:	
ADVERSE EVENTS OR ADVERSE DEVICE EFFECTS (ADE)	
1. Did any of the following occur since last visit?	
a. Reportable Hypoglycemic event:	
b. Definite or Probable Reportable Severe Hyperglycemic or DKA Event: ☐ Yes ☐ No If <u>Yes</u> , complete AE form and Severe Hyperglycemia or DKA Event form.	
c. Other reportable adverse event or adverse device effect (ADE): ☐ Yes ☐ No If <u>Yes</u> , complete AE or ADE form.	
MEDICAL CONDITIONS	
1. Did the participant report a new medical condition that does not meet the definition of a reportable adverse event and has not previously been recorded on the Medical Conditions Form?	
☐ Yes ☐ No	
If <u>Yes</u> , please complete the Medical Conditions Form.	
DEVICE DEFICIENCIES OR ISSUES	
1. Did the participant report having any reportable device deficiencies or issues while using a study device since the last contact?	
☐ Yes ☐ No	
If <u>Yes</u> , complete the Device Deficiencies or Issues Form.	
MEDICATIONS	
1. Did the participant report any changes or new medications since the last contact?	
☐ Yes ☐ No	
If <u>Yes</u> , please update the Medications Form.	
INSULIN	
1. Did the participant report any changes in insulin type or insulin delivery method since the last contact?	
☐ Yes ☐ No	
If <u>Yes</u> , please update the Insulin Form.	

CITY Real Time CGM Worksheet	
Subject	ID: Namecode:
CGM TF	RAINING PREVIOUS VISIT
1.	Was CGM training provided at the previous visit (randomization visit for CGM group and end of 26 week visit for BGM group?
	O Yes ONo
	1a. If No, enter reason:
2.	Select the training module that was delivered at the previous visit (select all that apply):
	Session 2: CGM Basics Session 3: Advanced CGM
	Session 4: Using CGM to Minimize Highs and Lows
	Note: Session 1: How CGM Works should have been delivered at the screening visit to all participants and reviewed as needed
3.	Name of study personnel who delivered CGM training at the previous visit:
CGM TF	RAINING CURRENT VISIT
1.	Was CGM training provided to the participant at this visit?
	O Yes ONo
	1a. If No, enter reason: If Yes, answer questions 2-3
2.	Select the training module that was delivered at this visit (select all that apply):
	☐ Session 2: CGM Basics
	Session 3: Advanced CGM Session 4: Using CGM to Minimize Highs and Lows
	Session 4: Using CGM to Minimize Highs and Lows
	Note: Session 1: How CGM Works should have been delivered at the screening visit to all participants and reviewed as needed
3.	Name of study personnel who delivered CGM training at this visit:

CGM SENSOR USE	
1. Base	d on participant's self-report, on average how many days per week does the participant use the study CGM?
C	00 01 02 03 04 05 06 07
1a. l	f <u>less than 6</u> , indicate reason (select all that apply):
	□Skin irritation □Wanted a break from using it daily □ Hesitant/uncomfortable using device □Uncomfortable or painful to wear □Alarms too frequently □Does not provide accurate readings □Too difficult to operate □Too busy to use it
	□Forget to use it
	□ Does not provide information that is helpful for diabetes management □ Too big or interfered with certain clothing or exercise/activity □ Other
lf	Other, complete the following: Describe:
2.	If 0 days, has the participant discontinued CGM use?
0	Yes O No
3. CGM?	Based on participant's self-report, on average how many weeks per month does the participant use the study
0	0 ○1 ○2 ○3 ○4 □Not applicable – 2 week visit
4.	Did the particiapnt have the LOW alarm turned on at the visit? ○ Yes ○ No
5.	Did the participant have the HIGH alarm turned on at the visit? O Yes O No

CGM	DATA REVIEW AND USE
1.	How frequently has the participant been reviewing his/her retrospective CGM data reports (i.e. either on Clarity website or report on Clarity phone application) ?
	O Daily
	O 4-6 times per week
	O 2-3 times per week
	O 1 time per week
	O 2-3 times per month
	O 1 time per month
	O < 1 time per month
	O Never
2.	Were the CGM data reviewed with the participant during the visit? O Yes O No
	2a. If No, enter reason:
	O Yes O No 2c. If Yes, were there any behavioral recommendations for diabetes management based on review of CGM data? O Yes O No
3.	In the past 30 days has the participant used the study CGM for dosing insulin without BGM fingerstick confirmation? O Yes O No
	3a. If YES, about how often in the past 7 days has the participant used CGM for dosing insulin without BGM fingerstick confirmation?
	O At least several times per day
	O 1 time per day
	O Some days but not every day
	O Never
	3b. If NO, select all that apply:
	 □ Checked with BGM out of habit □ Do not trust CGM values □ Not using CGM □ Other
	If <u>Other</u> , describe:

CGM VERIFICATION AND INVENTORY	
 Was the date and time on the CGM receiver or smartphone (if using as display device) reviewed prior to uploading CGM receiver to Clarity? O Yes O No 	
1a. If date/time not accurate, enter comment:	
2. Are the alarms/alerts on the CGM receiver working and audible? O Yes O No O Not Applicable	
If No, provide the participant with a new receiver and contact Dexcom Support.	
3.Was a new transmitter provided? ○ Yes ○ No □ Not applicable (52 week visit) A new transmitter must be assigned at the 13, 26, and 39 week visits (approximately every 3 months) Please ensure	
new transmitter linked to smartphone if applicable and data is being shared with clinic	
4. Was a new receiver provided?	
O Yes O No □Not applicable (52 week visit)	

CGM BENEFIT HANDOUT

Was the participant reminded about the benefits of using CGM?
 Yes ONo

*Use the CGM Benefit handout as a guide and provide to participants

PHONE: (813) 975-8690 FAX: (813) 975-8761 www.Jaeb.org

CITY Follow-up Complete the Visit Worksheet	
Patient ID: Namecode:	
SOURCE DOCUMENTATION	
1. Were any of the data for this visit/contact transcribed from another source (e.g., medical record, study visit worksheet) rather than <u>directly</u> entered on the website?	
∘ Yes ∘ No	
If yes, o	complete the following:
1a. Source used (check all that apply):	
	CRF worksheet
	Electronic medical record (EMR)
	Written patient chart
	Discharge summary
	Test/lab result
	Other